CAI
Caris Life Sciences, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
55.87
P/S
6.71
EV/EBITDA
1196.99
DCF Value
$-13.67
FCF Yield
0.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
66.4%
Operating Margin
5.6%
Net Margin
-8.4%
ROE
25.0%
ROA
-6.2%
ROIC
4.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $292.9M | $82.0M | $0.28 |
| FY 2025 | $812.0M | $-538.0M | $-1.90 |
| Q3 2025 | $216.8M | $24.3M | $0.08 |
| Q2 2025 | $181.4M | $-71.8M | $-1.87 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllLatest News
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.09
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.